NASDAQ:APENApollo Endosurgery Stock Price, Forecast & News

Apollo Endosurgery's stock was trading at $2.0650 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, APEN stock has decreased by 13.3% and is now trading at $1.79. View which stocks have been most impacted by Coronavirus.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Apollo Endosurgery in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Apollo Endosurgery.

Apollo Endosurgery is scheduled to release its next quarterly earnings announcement on Tuesday, July 28th 2020. View our earnings forecast for Apollo Endosurgery.

Apollo Endosurgery Inc (NASDAQ:APEN) released its quarterly earnings results on Monday, May, 4th. The biotechnology company reported ($0.49) earnings per share (EPS) for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.49). The biotechnology company had revenue of $10.72 million for the quarter, compared to analyst estimates of $9.07 million. Apollo Endosurgery had a negative return on equity of 565.93% and a negative net margin of 72.34%. View Apollo Endosurgery's earnings history.

1 brokerages have issued twelve-month price targets for Apollo Endosurgery's shares. Their forecasts range from $2.00 to $2.00. On average, they expect Apollo Endosurgery's stock price to reach $2.00 in the next year. This suggests a possible upside of 11.7% from the stock's current price. View analysts' price targets for Apollo Endosurgery.

News headlines about APEN stock have been trending neutral on Saturday, according to InfoTrie Sentiment. The research firm rates the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Apollo Endosurgery earned a media sentiment score of 0.4 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the near future. View the latest news aboutApollo Endosurgery.

Apollo Endosurgery saw a drop in short interest in May. As of May 15th, there was short interest totaling 177,900 shares, a drop of 10.0% from the April 30th total of 197,600 shares. Based on an average daily volume of 12,500 shares, the days-to-cover ratio is currently 14.2 days. Approximately 1.4% of the company's shares are sold short. View Apollo Endosurgery's Current Options Chain.

Some companies that are related to Apollo Endosurgery include T2 Biosystems (TTOO), Restoration Robotics (HAIR), BeyondAirInc . (XAIR), Venus Concept (VERO), Spectral Medical (EDTXF), PAVmed (PAVM), Titan Medical (TMDI), SANUWAVE Health (SNWV), AIT Therapeutics (AITB), BRAINSWAY LTD/S (BWAY), Pro-Dex (PDEX), Nephros (NEPH), Nephros (NEPHD), Sensus Healthcare (SRTS) and STRATA Skin Sciences (SSKN). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Apollo Endosurgery investors own include Obalon Therapeutics (OBLN), NovaBay Pharmaceuticals (NBY), NovaBay Pharmaceuticals (NBY), Tonix Pharmaceuticals (TNXP), Second Sight Medical Products (EYES), Inovio Pharmaceuticals (INO), Nektar Therapeutics (NKTR), Novavax (NVAX), Onconova Therapeutics (ONTX) and Opko Health (OPK).

Apollo Endosurgery trades on the NASDAQ under the ticker symbol "APEN."

Apollo Endosurgery's stock is owned by many different institutional and retail investors. Top institutional investors include Stonepine Capital Management LLC (7.97%), Gagnon Securities LLC (4.79%), Prosight Management LP (1.60%), Falcon Point Capital LLC (0.17%) and Private Advisors LLC (0.10%). Company insiders that own Apollo Endosurgery stock include Matthew S Crawford, Stefanie L Cavanaugh, Stonepine Capital, LP and Todd Newton. View institutional ownership trends for Apollo Endosurgery.

APEN stock was sold by a variety of institutional investors in the last quarter, including Falcon Point Capital LLC. View insider buying and selling activity for Apollo Endosurgery.

APEN stock was purchased by a variety of institutional investors in the last quarter, including Prosight Management LP, Stonepine Capital Management LLC, Private Advisors LLC, and Gagnon Securities LLC. Company insiders that have bought Apollo Endosurgery stock in the last two years include Matthew S Crawford, Stefanie L Cavanaugh, Stonepine Capital, LP, and Todd Newton. View insider buying and selling activity for Apollo Endosurgery.

Shares of APEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of APEN stock can currently be purchased for approximately $1.79.

Apollo Endosurgery has a market capitalization of $37.82 million and generates $50.71 million in revenue each year. The biotechnology company earns $-27,430,000.00 in net income (profit) each year or ($1.53) on an earnings per share basis. Apollo Endosurgery employs 215 workers across the globe.

The official website for Apollo Endosurgery is www.apolloendo.com.

Apollo Endosurgery's mailing address is 1120 SOUTH CAPITAL OF TX HWY BUILDING 1 SUITE 300, AUSTIN TX, 78746. The biotechnology company can be reached via phone at 512-279-5100 or via email at [email protected]